Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia

Blood

Volumn 98, Issue 6, 2001, Pages 1732-1738

  Huntly, Brian J P ^{a,b,c,d,e,f,g,h}   Reid, Alistair G ^{a,b,c,d,e,f,g,h}   Bench, Anthony J ^{a,b,c,d,e,f,g,h}   Campbell, Lynda J ^{a,b,c,d,e,f,g,h}   Telford, Nick ^{a,b,c,d,e,f,g,h}   Shepherd, Patricia ^{a,b,c,d,e,f,g,h}   Szer, Jeff ^{a,b,c,d,e,f,g,h}   Miles Prince, H ^{a,b,c,d,e,f,g,h}   Turner, Paul ^{a,b,c,d,e,f,g,h}   Grace, Colin ^{a,b,c,d,e,f,g,h}   Nacheva, Elizabeth P ^{a,b,c,d,e,f,g,h}   Green, Anthony R ^{a,b,c,d,e,f,g,h}  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ST VINCENT S HOSPITAL   (Australia)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d WESTERN GENERAL HOSPITAL   (United Kingdom)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g ALFRED HOSPITAL   (Australia)

^h Digital Scientific Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ADULT; ARTICLE; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL TIME;

EID: 0035885928     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.6.1732     Document Type: Article

References (56)

1. Faderl S, Talpaz M, Estrav Z, O'Brien S, Kuzrock R, Kantarjian H. The biology of chronic myeloid leakemia. N Engl J Med. 1999;341:167-172.
2. Deininger M, Goldman J, Melo J. The molecular biology of chronic myeloid leukemia. Blood 2000;96:3343-3356.
3. Sawyers C. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
4. Bartram C, de Klein A, Hagemeijer A. Translocation of c-abl oncogene correlates with the presence of the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280.
5. Groffen J, Stephenson J, Heisterkamp N, de Klein A, Bartram C, Grosveld G. Philadelphia chromosome breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-99.
6. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290-293.
7. bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-830.
8. Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale P, Goffen J. Acute leukemia in bcr-abl transgenic mice. Nature. 1990;344:251-253.
9. Elefanty A, Hariharan I, Cory S. BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 1990;9:1069-1078.
10. Voncken J, Kaartinen V, Pattengale P, Germeraad W, Groffen J, Heisterkamp N. BCR/ABL p210 and p190 cause distinct leukemia in transgenic mice. Blood. 1995;86:4603-4611.
11. Zhang X, Ren R. Bcr-abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukaemia. Blood. 1998;92:3829-3840.
12. Pear W, Miller J, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving p210 bcr/abl transduced bone marrow. Blood. 1998;92:3780-3792.
13. 1-positive leukemias. Blood. 1998;91:2067-2075.
14. Huettner C, Zhang P, Van Etten R, Tenen D. Reversibility of acute B-cell leukemia induced by BCR-ABL1. Nat. Genet. 2000;24:57-60.
15. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol. 1988;25:20-34.
16. Druker B, Sawyers C, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
17. Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukaemia. N Engl J Med. 2001;344:1031-1037.
18. Peters D, Hoover R, Gertach M, et al. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukaemia and primary cells from patients with chronic myeloid leukaemia. Blood. 2001;97:1404-1411.
19. Reichert A, Heisterkamp N, Daley G, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukaemia in P190 mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399-1403.
20. Sokal J, Cox E, Baccarini M. Prognostic discrimination in "good risk" chronic granulocytic leukemia. Blood. 1984;63:1352-1357.
21. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. J Natl Cancer Inst. 1998;90:850-858.
22. Grand F, Kulkarni S, Chase A, Goldman JM, Cross NCP. Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukaemia. Cancer Res. 1999;59:3870-3874.
23. Dewald G, Wyatt W, Silver R. Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leuk Lymphoma. 1999;34:481-491.
24. Herens C, Tassin F, Lemaire V, et al. Deletion of the 5′-ABL region: a recurrent anomaly detected by fluorescence in situ hybridisation in about 10% of Philadelphia-positive chronic myeloid leukaemia patients. Br J Haematol. 2000;110:214-216.
25. Sinclair PB, Nacheva EP, Laversha M, et al. Large deletions at the t(9; 22) breakpoint are common and may identity a poor-prognosis subgroup of patients with chronic myeloid leukaemia. Blood. 2000;95:738-744.
26. Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci U S A. 1999;96:203-207.
27. Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18:2676-2680.
28. Allan N, Richards S, Shepherd P, et al. UK Medical Research Council randomised multicentre trial of interferon-alpha for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet. 1995;345:1392-1397.
29. Sinclair P, Green A, Grace C, Nacheva E. Improved sensitivity of BCR-ABL detection: a triple probe three-color fluorescence in situ hybridization system. Blood. 1997;90:1395-1402.
30. Dewald G, Wyatt W, Juneau A, et al. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 1998;91:3357-3365.
31. Calabrese G, L S, Franchi P, et al. Complex translocations of the Ph chromosome and Ph negative CML arise from similar mechanisms, as evidenced by FISH analysis. Cancer Genet Cytogenet. 1994;78:153-159.
32. Potter A, Watmore A, Cooke P, Lilleyman J, Sokol R. Significance of non-standard Philadelphia chromosomes in chronic granulocytic leukaemia. Br J Cancer. 1981;44:51-54.
33. 1 chronic myeloid leukemia. Cancer Genet Cytogenet. 1984;12: 225-228.
34. Gratwohl A, Hermans J, Goldman J, et al. Risk assessment for patients with chronic myeloid leukaemia before allogenic blood or bone marrow transplantation. Lancet. 1998;352:1087-1092.
35. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon-alpha 2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994;330:820-825.
36. Guiholt F, Chastang C, Michalet M, Geurci A, Harouseau J-L, Maloisel F. Interferon alfa 2b combined with cytarabine versus interferon alpha alone in chronic myelogenous leukemia. N Engl J Med. 1997;337:223-229.
37. Hehlmann R. Trial of IFN or STI 571 before proceeding to allografting for CML. Leukemia. 2000;14:1560-1562.
38. Tura S, Kantarjian H, Melo J, Giralt S, Talpaz M. Chronic myelogenous leukemia: disease biology and current and future therapeutic strategies. In: Schectner G, Berliner N, Telen M, eds. Hematology 2000. San Francisco: American Society of Hematology, 2000:90-109.
39. 1 and other translocations in CML. Cancer. 1980;46:2221-2226.
40. De Braekleer M. Variant translocations in chronic myeloid leukemia. Cytogenet Cell Genet. 1987;44:215-222.
41. Melo J. BCR-ABL gene variants. In: Goldman J, ed. Chronic Myeloid Leukaemia. London, United Kingdom: Baillibre Tindall: 1997:203-222.
42. Melo J, Hochhaus A, Yan X-H, Goldman J. Lack of correlation between ABL-BCR expression and response to interferon-α in chronic myeloid leukaemia. Br J Haematol. 1996;92:684-686.
43. Asimakopoulos FA, Green AR. Deletions of chromosome 20q and the pathogenesis of myeloproliferative disorders. Br J Haematol. 1996;95:219-226.
44. Birney E, Bateman A, Clamp M, Hubbard T. Mining the draft human genome. Nature. 2001;409:827-828.
45. Versteege I, Sevent N, Lange J, et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature. 1998;394:203-206.
46. Ruttledge M, Sarrazin J, Rangaratnam S, et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat Genet. 1994;6:180-184.
47. Buijs A, Sherr S, van Baal S, et al. Translocation (12;22)(p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. Oncogene. 1995;10:1511-1519.
48. Monica K, Galili N, Nourse J, Saltman D, Cleary M. PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1. Mol Cell Biol 1991;11:6149-6157.
49. Dreyer S, Zhou G, Baldini A, et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet. 1998;19:47-50.
50. Millward T, Zolnierowicz S, Hemmings B. Regulation of the protein kinase cascades by protein phosphatase 2A. Trends Biochem Sci. 1999;24:186-191.
51. Colicelli J, Nicolette C, Birchmeier C, Rodgers L, Riggs M, Wigler M. Expression of three mammalian cDNAs that interfere with RAS fuction in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A. 1991;88:2913-2917.
52. Maekawa M, Ishizaki T, Boku S, et al. Signalling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999;285:895-898.
53. Dirksen U, Hattenhorst U, Schneider P, et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common β chain in children with acute myeloid leukaemia associated with respiratory failure. Blood. 1998;92:1097-1103.
54. Grana X, De Luca A, Sang N, et al. PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A. 1994;91:3834-3838.
55. Wada C, Shionoya S, Fujino Y, et al. Genomic instability of microsatellite repeats and its association with the evolution of chronic myelogenous leukemia. Blood. 1994;83:3449-3456.
56. Silly H, Chase A, Mills K, et al. No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis. Leukemia. 1994;8:1923-1928.